Santa Monica, California headquartered Kite Pharma Inc.'s stock finished last Friday's session 0.88% lower at $47.21. A total volume of 580,324 shares was traded. The Company's shares have advanced 2.81% in the previous three months and 5.29% on an YTD basis. The stock is trading below its 50-day moving average by 4.03%. Additionally, shares of Kite Pharma, which focuses on the development and commercialization of novel cancer immunotherapy products, have a Relative Strength Index (RSI) of 44.13.
On January 04th, 2017, research firm ROTH Capital initiated a 'Buy' rating on the Company's stock, with a target price of $68 per share.
On January 10th, 2017, Kite and Shanghai Fosun Pharmaceutical (Group) Co., Ltd, announced a joint venture, to develop, manufacture and commercialize axicabtagene ciloleucel in China with the option to include additional products, including two T cell receptor product candidates from Kite. Axicabtagene ciloleucel, Kite's lead product candidate, is an investigational chimeric antigen receptor T-cell therapy under development for the treatment of B-cell lymphomas and leukemia. Under terms of the agreement, Fosun Pharma will provide the RMB equivalent of $20 million in funding to support clinical development and manufacturing activities and Kite will provide certain technical transfer services to the joint venture. Visit us today and download your complete report on KITE for free at:
On Friday, shares in Menlo Park, California headquartered BioPharmX Corp. ended the session 0.63% higher at $0.43. The stock recorded a trading volume of 276,659 shares. The Company's shares have gained 7.92% in the last one month, 31.62% in the previous three months, and 15.43% since the start of this year. The stock is trading 20.45% above its 50-day moving average. Moreover, shares of BioPharmX, which focuses on the development of novel drug delivery products for women's health and dermatology markets, have an RSI of 57.69.
On January 04th, 2017, BioPharmX announced the on-time completion of enrollment in the OPAL (tOPicAL Minocycline Gel) study - a Phase-2b dose finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vulgaris. The 12-week, multi-center, randomized, double-blind, three-arm, vehicle-controlled OPAL study involves 225 individuals, aged 9 to 40, who have moderate-to-severe inflammatory, non-nodular acne vulgaris. The study's primary endpoint is absolute mean change from baseline in inflammatory lesion counts at week 12. Results of the study will be used to guide Phase-3 trial design. The complimentary research report on BPMX can be accessed at:
Waltham, Massachusetts headquartered OvaScience Inc.'s shares climbed 0.65%, closing the session at $1.56 with a total trading volume of 408,925 shares. The stock has gained 1.96% on an YTD basis. The Company's shares are trading 42.62% below their 50-day moving average. Additionally, shares of OvaScience, which discovers, develops, and commercializes new fertility treatment options for women worldwide, have an RSI of 31.58.
On December 23rd, 2017, OvaScienceSM announced the grant of inducement awards to purchase an aggregate of 356,000 shares of its common stock to 16 newly hired employees. In connection with the Company's previously announced corporate restructuring, OvaScienceSM expects that 278,000 of these options will be cancelled, leaving 78,000 options remaining. The options are exercisable at a price of $3.23 per share, the closing price per share of the Company's common stock on the date of grant, and will vest over four years. Register for free on Stock-Callers.com and download the PDF research report on OVAS at:
Last Friday at the close, Tarrytown, New York headquartered Regeneron Pharmaceuticals Inc.'s stock recorded a trading volume of 781,420 shares, and ended the session 0.23% lower at $362.56. The Company's shares are trading below their 50-day moving average by 5.26%. Shares of the Company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide, have an RSI of 42.62.
On January 05th, 2017, Regeneron Pharma and Sanofi announced that they will appeal the injunction granted today by the US District Court for the District of Delaware preventing the marketing, selling or manufacturing of Praluent® in the US during the term of two Amgen's patents.
On January 06th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with a decrease of the target price from $626 a share to $598 a share. Get free access to your research report on REGN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA